Iambic Therapeutics · 公司档案
Iambic Therapeutics · 美国 · AI与模型数据
登记关注方向:AI药物发现、小分子设计。关注方向是目录字段;具体能力请核查下方来源与项目证据。
别名:Iambic
公开已核验进展
Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Iambic 官方公告,已提交 IAM217 的 IND 申请。提交申请不等于监管批准,也不代表临床疗效已获证实。
Iambic 与 AbbVie 宣布 AI 药物发现合作
Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据双方在 Iambic 官网发布的公告,将利用 Iambic 的 AI 平台合作开展药物发现,提高候选药物识别效率。属于公司宣布的合作,未独立验证研发成效。
Iambic 与拜耳合作推进 AI 小分子发现
Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Iambic 官方公告,拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现;尚非临床疗效结论。
合作、许可与并购时间线
Iambic 与 AbbVie 宣布 AI 药物发现合作
Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据双方在 Iambic 官网发布的公告,将利用 Iambic 的 AI 平台合作开展药物发现,提高候选药物识别效率。属于公司宣布的合作,未独立验证研发成效。
Iambic 与拜耳合作推进 AI 小分子发现
Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Iambic 官方公告,拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现;尚非临床疗效结论。
以上来自最新 3 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。
公开来源记录与官方目录
目录信息与已保存正文分别标注;历史正文保留,目录条目不用于研究摘要或事件证据。
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Iambic official newsroom · 官方目录信息,正文未采集 · 来源发布:November 18, 2026 · 本站收录:Sun Nov 22 2026 04:37:20 GMT+0000 (Coordinated Universal Time)
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Iambic official newsroom · 官方目录信息,正文未采集 · 来源发布:November 16, 2026 · 本站收录:Sun Nov 22 2026 04:37:20 GMT+0000 (Coordinated Universal Time)
Iambic to participate in Jefferies Global Healthcare Conference
Iambic official newsroom · 官方目录信息,正文未采集 · 来源发布:November 9, 2026 · 本站收录:Sun Nov 22 2026 04:37:20 GMT+0000 (Coordinated Universal Time)
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Mon Oct 26 2026 12:07:42 GMT+0000 (Coordinated Universal Time)
IAM1363, now in a Phase 1/1b stud y , was designed using Iambic’s molecular superintelligence platform and brought to clinic al development in approximately two years D ata presented at ESMO 2026 demonstrates IAM1363 was
Iambic Announces Pricing of Initial Public Offering
Iambic official newsroom · 行业原文收录 · 来源发布:Wed Oct 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 15 2026 00:07:40 GMT+0000 (Coordinated Universal Time)
SAN DIEGO, Calif., October 14, 2026 – Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pr
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)
In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intr
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)
− Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)
Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse data
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · 行业原文收录 · 来源发布:Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Iambic to participate in upcoming investor conferences
Iambic official newsroom · 行业原文收录 · 来源发布:Mon May 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:08:55 GMT+0000 (Coordinated Universal Time)
Iambic to Participate in Upcoming Investor Conferences SAN DIEGO, CA – May 11, 2026 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced
Iambic to Participate in April Investor Conferences
Iambic official newsroom · 行业原文收录 · 来源发布:Thu Apr 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:09:13 GMT+0000 (Coordinated Universal Time)
SAN DIEGO, CA – April 2, 2026 – Iambic , a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery and development platform, today announced its participation in u
Iambic to Participate in March Investor Conferences
Iambic official newsroom · 行业原文收录 · 来源发布:Mon Mar 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:09:23 GMT+0000 (Coordinated Universal Time)
SAN DIEGO, CA – March 2, 2026 -- Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery platform, today announced its participation in upcoming March in
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Iambic official newsroom · 行业原文收录 · 来源发布:Mon May 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Wed Nov 18 2026 13:09:20 GMT+0000 (Coordinated Universal Time)
Last year, we introduced Enchant , a multimodal transformer model that redefined drug discovery prediction in low-data regimes. Enchant is trained on many data modalities from dozens of external and internal sources, acr
已验证的官方与订阅来源
- Iambic official newsroom · 采集已启用 · 官方目录采集;不采集正文 · 最近成功 Sun Nov 22 2026 16:07:26 GMT+0000 (Coordinated Universal Time)
来源验证与持续采集分别显示;原文收录不自动成为已核验事件。
专题指南:从原文到判断
按任务比较模型,按证据追踪合作;每篇保留原始出处与更新日期。
虚拟细胞、AI 模型与公司:应该怎样比较?
按输入、输出、任务和验证条件比较单细胞模型、结构预测与蛋白设计,并区分模型论文与公司能力。
阅读指南 · 更新 2026-10-08
AI 制药公司合作时间线:从公告读到证据
用真实官方公告区分合作主体、首付款、条件性里程碑和研发进度,并建立可追溯的合作时间线。
阅读指南 · 更新 2026-10-08
每周 AI 制药信息怎么读:公司动态、研究进展与覆盖缺口
建立每周阅读顺序,分清公告、论文与临床结果;理解本站本周收录的时间窗口、分母和来源覆盖。
阅读指南 · 更新 2026-10-08